{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:39:30Z","timestamp":1790199570297,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jem-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Emergency Medicine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jemermed.2021.07.045","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T17:40:55Z","timestamp":1631295655000},"page":"674-682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation and Management of Thrombotic Thrombocytopenic Purpura in the Emergency Department"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4770-8869","authenticated-orcid":false,"given":"Brit","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel E.","family":"Bridwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivon","family":"Manchanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3276-8375","authenticated-orcid":false,"given":"Michael","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jemermed.2021.07.045_bib0001","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ajh.2830500203","article-title":"Increasing mortality from thrombotic thrombocytopenic purpura in the United States\u2013analysis of national mortality data, 1968\u20131991","volume":"50","author":"T\u00f6r\u00f6k","year":"1995","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0002","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1538-7836.2005.01436.x","article-title":"The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency","volume":"3","author":"Terrell","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12185-009-0476-1","article-title":"Pathophysiology of thrombotic thrombocytopenic purpura","volume":"91","author":"Tsai","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0004","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/pbc.24612","article-title":"Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features","volume":"60","author":"Reese","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0005","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/S2352-3026(16)30018-7","article-title":"Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy","volume":"3","author":"Mariotte","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0006","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood-2013-04-496752","article-title":"Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura","volume":"122","author":"Deford","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0007","doi-asserted-by":"crossref","first-page":"e33029","DOI":"10.1371\/journal.pone.0033029","article-title":"Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan","volume":"7","author":"Matsumoto","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0008","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/bloodadvances.2017005124","article-title":"Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015","volume":"1","author":"Page","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0009","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1365-2141.2008.07276.x","article-title":"Regional UK TTP registry: correlation with laboratory ADAMTS 13 analysis and clinical features","volume":"142","author":"Scully","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0010","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1182\/blood-2016-12-758656","article-title":"Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura","volume":"130","author":"Alwan","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0011","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0012","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1537-2995.2009.02528.x","article-title":"Thrombotic thrombocytopenic purpura at the Johns Hopkins Hospital from 1992 to 2008: clinical outcomes and risk factors for relapse","volume":"50","author":"Zhan","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0013","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1182\/blood-2009-09-243790","article-title":"Survival and relapse in patients with thrombotic thrombocytopenic purpura","volume":"115","author":"Kremer Hovinga","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0014","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12959-018-0189-x","article-title":"Thrombotic thrombocytopenic purpura (TTP)-like syndrome in the HIV era","volume":"16","author":"Louw","year":"2018","journal-title":"Thromb J"},{"issue":"112","key":"10.1016\/j.jemermed.2021.07.045_bib0015","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1038\/ki.2008.610","article-title":"Mechanisms of microvascular thrombosis in thrombotic thrombocytopenic purpura","author":"Tsai","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0016","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/blood-2017-04-636431","article-title":"Pathophysiology of thrombotic thrombocytopenic purpura","volume":"130","author":"Sadler","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0017","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/asheducation-2018.1.530","article-title":"Clinical and laboratory diagnosis of TTP: an integrated approach","volume":"2018","author":"Chiasakul","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0018","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1182\/blood.V98.9.2730","article-title":"Changes in health and disease of the metalloprotease that cleaves von Willebrand factor","volume":"98","author":"Mannucci","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0019","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1537-2995.2012.03934.x","article-title":"First symptoms in patients with thrombotic thrombocytopenic purpura: what are they and when do they occur?","volume":"53","author":"Griffin","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0020","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/bjh.13658","article-title":"Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative","volume":"171","author":"Bendapudi","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0021","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/imj.12935","article-title":"Diagnosis and management of thrombotic thrombocytopenic purpura (TTP) in Australia: findings from the first 5 years of the Australian TTP\/thrombotic microangiopathy registry","volume":"46","author":"Blombery","year":"2016","journal-title":"Intern Med J"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0022","doi-asserted-by":"crossref","first-page":"4060","DOI":"10.1182\/blood-2010-07-271445","article-title":"How I treat patients with thrombotic thrombocytopenic purpura: 2010","volume":"116","author":"George","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0023","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1056\/NEJMcp053024","article-title":"Clinical practice. Thrombotic thrombocytopenic purpura","volume":"354","author":"George","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0024","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/asheducation-2004.1.407","article-title":"Recent advances in thrombotic thrombocytopenic purpura","author":"Sadler","year":"2004","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0025","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1111\/trf.14357","article-title":"The importance of clinical judgment for the diagnosis of thrombotic thrombocytopenic purpura","volume":"57","author":"George","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0026","first-page":"80","article-title":"Acute pancreatitis-induced thrombotic thrombocytopenic purpura","volume":"13","author":"Gurjar","year":"2012","journal-title":"JOP"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0027","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/jca.21248","article-title":"Ten patient stories illustrating the extraordinarily diverse clinical features of patients with thrombotic thrombocytopenic purpura and severe ADAMTS13 deficiency","volume":"27","author":"George","year":"2012","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0028","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2003-01-0193","article-title":"ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients","volume":"102","author":"Vesely","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0029","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/jth.12826","article-title":"Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity","volume":"13","author":"Zafrani","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0030","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/jth.12790","article-title":"Reference Center for Thrombotic Microangiopathies. Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center","volume":"13","author":"Benhamou","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0031","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.amjmed.2005.02.019","article-title":"Incidence and prognosis of acute heart failure in the thrombotic microangiopathies","volume":"118","author":"Gami","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0032","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/ndt\/gfl127","article-title":"Acute myocardial infarction in thrombotic microangiopathies\u2013clinical characteristics, risk factors and outcome","volume":"21","author":"Patschan","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0033","doi-asserted-by":"crossref","first-page":"357","DOI":"10.7326\/0003-4819-91-3-357","article-title":"The heart and cardiac conduction system in thrombotic thrombocytopenic purpura. A clinicopathologic study of 17 autopsied patients","volume":"91","author":"Ridolfi","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0034","doi-asserted-by":"crossref","first-page":"937","DOI":"10.5858\/1999-123-0937-MMNITT","article-title":"Massive myocardial necrosis in thrombotic thrombocytopenic purpura: a case report and review of the literature","volume":"123","author":"Podolsky","year":"1999","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0035","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1177\/107602960000600212","article-title":"Sudden cardiac death from thrombotic thrombocytopenic purpura","volume":"6","author":"Wajima","year":"2000","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0036","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1538-7836.2009.03285.x","article-title":"Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS 13","volume":"7","author":"Hughes","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0037","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1537-2995.2007.01534.x","article-title":"Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review","volume":"48","author":"Hawkins","year":"2008","journal-title":"Transfusion"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0038","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/ejh.12222","article-title":"Pulmonary involvement in patients with thrombotic thrombocytopenic purpura","volume":"92","author":"Nokes","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0039","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1182\/blood-2003-11-4035","article-title":"Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura","volume":"103","author":"Zheng","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0040","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0041","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/(SICI)1098-1101(1998)13:1<16::AID-JCA3>3.0.CO;2-C","article-title":"Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura","volume":"13","author":"Cohen","year":"1998","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0042","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1751-553X.2011.01380.x","article-title":"International Council for Standardization in Haematology (ICSH). ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes","volume":"34","author":"Zini","year":"2012","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0043","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1365-2141.1962.tb06541.x","article-title":"Microangiopathic haemolytic anaemia: the possible role of vascular lesions in pathogenesis","volume":"8","author":"Brain","year":"1962","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0044","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1681\/ASN.2004100861","article-title":"Hemolytic uremic syndrome","volume":"16","author":"Noris","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0045","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00281-014-0416-x","article-title":"Hemolytic uremic syndrome","volume":"36","author":"Mele","year":"2014","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0046","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ki.1987.206","article-title":"HUS and TTP: variable expression of a single entity","volume":"32","author":"Remuzzi","year":"1987","journal-title":"Kidney Int"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0047","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000167066","article-title":"Renal involvement in patients with thrombotic thrombocytopenic purpura","volume":"6","author":"Eknoyan","year":"1986","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0048","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1182\/blood-2004-11-4490","article-title":"ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases","volume":"106","author":"Rieger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0049","doi-asserted-by":"crossref","first-page":"546","DOI":"10.5858\/arpa.2013-0170-OA","article-title":"Use of the ADAMTS13 activity assay improved the accuracy and efficiency of the diagnosis and treatment of suspected acquired thrombotic thrombocytopenic purpura","volume":"138","author":"Barrows","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0050","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1365-2141.2005.05420.x","article-title":"FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay","volume":"129","author":"Kokame","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0051","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1160\/TH12-08-0565","article-title":"Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies","volume":"109","author":"Mackie","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0052","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/j.1537-2995.2006.00914.x","article-title":"Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity","volume":"46","author":"Kato","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0053","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1538-7836.2006.01758.x","article-title":"A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption\/ionization time-of-flight (SELDI-TOF)-mass spectrometry","volume":"4","author":"Jin","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0054","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ajh.20097","article-title":"Simplified assay for VWF cleaving protease (ADAMTS13) activity and inhibitor in plasma","volume":"76","author":"Knovich","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0055","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0056","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/jth.13882","article-title":"External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment","volume":"16","author":"Li","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0057","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/trf.15954","article-title":"Diagnostic accuracy of the PLASMIC score in patients with suspected thrombotic thrombocytopenic purpura: a systematic review and meta-analysis","volume":"60","author":"Paydary","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0058","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0059","doi-asserted-by":"crossref","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","article-title":"French Reference Center for Thrombotic Microangiopathies. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0060","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0061","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ajh.21881","article-title":"Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura","volume":"86","author":"Cataland","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0062","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1182\/blood-2014-11-551580","article-title":"How I treat refractory thrombotic thrombocytopenic purpura [published correction appears in Blood 2017;130:1684]","volume":"125","author":"Sayani","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0063","first-page":"15","article-title":"Management of thrombotic thrombocytopenic purpura: current perspectives","volume":"5","author":"Blombery","year":"2014","journal-title":"J Blood Med"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0064","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1423-0410.2006.00747.x","article-title":"Treatment of thrombotic thrombocytopenic purpura","volume":"90","author":"Fontana","year":"2006","journal-title":"Vox Sang"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0065","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/jca.21302","article-title":"Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research","volume":"29","author":"Sarode","year":"2014","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0066","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00277-009-0877-5","article-title":"Italian TTP Study Group. High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study","volume":"89","author":"Balduini","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0067","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1600-0609.2009.01292.x","article-title":"Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature","volume":"83","author":"Elliott","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0068","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","volume":"40","author":"Froissart","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0069","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00277-004-0964-6","article-title":"Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura","volume":"84","author":"Reddy","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0070","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ajh.20166","article-title":"Rituximab for treatment of refractory \u2044 relapsing thrombotic thrombocytopenic purpura (TTP)","volume":"77","author":"Ahmad","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0071","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1182\/blood-2014-10-559211","article-title":"The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura","volume":"125","author":"Lim","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0072","first-page":"e5263","article-title":"Clinical efficacy and safety profile of caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"11","author":"Maqsood","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0073","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1111\/jth.13716","article-title":"Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura","volume":"15","author":"Peyvandi","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0074","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/tme.12615","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial)","volume":"29","author":"Estcourt","year":"2019","journal-title":"Transfus Med"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0075","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/blood.2020006052","article-title":"Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura","volume":"137","author":"Goshua","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0076","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/vox.12274","article-title":"Platelet transfusion in thrombotic thrombocytopenic purpura","volume":"109","author":"Otrock","year":"2015","journal-title":"Vox Sang"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0077","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/jca.21279","article-title":"Platelet transfusions and bleeding complications associated with plasma exchange catheter placement in patients with presumed thrombotic thrombocytopenic purpura","volume":"28","author":"Duffy","year":"2013","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0078","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1001\/jama.2016.9185","article-title":"Clinical practice guidelines from the AABB: red blood cell transfusion thresholds and storage","volume":"316","author":"Carson","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0079","first-page":"429","article-title":"Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP","volume":"82","author":"Bobbio-Pallavicini","year":"1997","journal-title":"Haematologica"},{"key":"10.1016\/j.jemermed.2021.07.045_bib0080","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1111\/jth.15027","article-title":"Describing the point prevalence and characteristics of venous thromboembolism in patients with thrombotic thrombocytopenic purpura","volume":"18","author":"Tse","year":"2020","journal-title":"J Thromb Haemost"}],"container-title":["The Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467921006272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467921006272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:48:30Z","timestamp":1760028510000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0736467921006272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":80,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0736467921006272"],"URL":"https:\/\/doi.org\/10.1016\/j.jemermed.2021.07.045","relation":{},"ISSN":["0736-4679"],"issn-type":[{"value":"0736-4679","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation and Management of Thrombotic Thrombocytopenic Purpura in the Emergency Department","name":"articletitle","label":"Article Title"},{"value":"The Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jemermed.2021.07.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}